3-hydroxymethyl-3-methyl-phthalide | 99059-03-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 3-hydroxymethyl-3-methyl-phthalide
• 英文别名: 3-Hydroxymethyl-3-methyl-phthalid；rac-3-(hydroxymethyl)-3-methyl-3-hydroisobenzofuran-1-one；3-(Hydroxymethyl)-3-methyl-2-benzofuran-1-one
• CAS: 99059-03-7
• 化学式: C₁₀H₁₀O₃
• 分子量: 178.188
• InChiKey: IYOFXKAUKCDZRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-丙-1-烯-2-基苯甲酸 在 甲基三氧化铼(VII) 双氧水 作用下， 以 氯仿 、 水 为溶剂， 反应 4.0h， 以73%的产率得到3-hydroxymethyl-3-methyl-phthalide
  参考文献：
  名称：

  Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use

  摘要：

  内部掩盖的新戊基磺酰酯前药，包含这种前药的药物组合物，以及使用这种前药和组合物治疗疾病的方法被披露。具体来说，披露了展现增强口服生物利用度的阿卡姆普罗酸前药以及使用阿卡姆普罗酸前药治疗神经退行性疾病、精神障碍、情绪障碍、焦虑障碍、躯体形式障碍、运动障碍、物质滥用障碍、暴饮暴食障碍、皮层扩散性抑郁相关障碍、耳鸣、睡眠障碍、多发性硬化症和疼痛的方法。

  公开号：

  US20090099253A1

文献信息

• Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
  申请人：Li Yunxiao

  公开号：US20090099253A1

  公开（公告）日：2009-04-16

  Internally masked neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.

  内部掩盖的新戊基磺酰酯前药，包含这种前药的药物组合物，以及使用这种前药和组合物治疗疾病的方法被披露。具体来说，披露了展现增强口服生物利用度的阿卡姆普罗酸前药以及使用阿卡姆普罗酸前药治疗神经退行性疾病、精神障碍、情绪障碍、焦虑障碍、躯体形式障碍、运动障碍、物质滥用障碍、暴饮暴食障碍、皮层扩散性抑郁相关障碍、耳鸣、睡眠障碍、多发性硬化症和疼痛的方法。
• Electrosynthesis of Benzolactones by Nickel-Catalyzed Carboxylation of Epoxide-Functionalized Aromatic Halides
  作者：Patricia Tascedda、Elisabet Duñach

  DOI：10.1055/s-2000-6486

  日期：2000.2

  The electrochemical, nickel-catalyzed carbon dioxide incorporation into 2-haloaryl epoxides led chemoselectively to different carboxylated products according to the nature of the substrate and to the catalytic system. Whereas terminal epoxide derivatives led to cyclic carbonates in good yields, disubstituted epoxides reacted through a first carbon-halogen bond carboxylation followed by epoxide ring opening. Five-membered ring benzolactones were selectively formed with cyclam as the ligand, whereas 6-membered ring isocoumarine derivatives were obtained using 2,2′-bipyridine.

  根据底物性质和催化体系的不同，电化学镍催化二氧化碳掺入 2-卤代环氧化物的化学选择性地产生了不同的羧化产物。末端环氧化物衍生物能以良好的收率生成环状碳酸盐，而二取代环氧化物则首先通过碳-卤键羧化反应，然后再进行环氧化物开环反应。以环己胺为配体可选择性地生成五元环苯甲内酯，而使用 2,2′-联吡啶则可获得六元环异香豆素衍生物。
• [EN] INTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE<br/>[FR] PROMÉDICAMENTS DE L'ACAMPROSATE À LIBÉRATION PAR CYCLISATION DE NÉOPENTYLSULFONYLESTER À MASQUAGE INTERNE, LEURS COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：XENOPORT INC

  公开号：WO2009052191A1

  公开（公告）日：2009-04-23

  Internally masked neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.
• The Reaction of cis- and trans-Stilbene-2-carboxylic Acids with Peroxyacids¹
  作者：GIANCARLO BERTI

  DOI：10.1021/jo01089a011

  日期：1959.7